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Summary
Left atrial appendage occlusion is based on the obser-
vation that most thrombi of atrial fibrillation patients 
are located in the appendage. The only published ran-
domised trial available so far has demonstrated equal 
effectiveness of the studied Watchman device com-
pared to warfarin in reducing embolic events and over-
all mortality. Commercially available devices have all 
shown safety and effectiveness in clinical registries, 
even when only antiplatelet agents are given immedi-
ately after the procedure and stopped after a few 
months. Current indications are mainly restricted to 
patients who are at risk for, or have complications from, 
oral anticoagulants or object to taking them. Further 
technical improvements in the devices and the implan-
tation techniques are important to support the propa-
gation of this procedure.
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Background and rationale
The left atrial appendage (LAA) is an embryonic rem-
nant of the left atrium, bearing various shapes and 
morphologies of a long cul-de-sac. Its complex structure 
with areas of relative slow flow predisposes to stasis, 
particularly during atrial fibrillation (AF) episodes due 
to failure of its contractile function, as has been docu-
mented on transoesophageal echocardiography (TOE) 
examination with spontaneous echocardiographic con-
trast or pulsed-wave Doppler during bouts of AF [1, 2]. 
It has been shown that in patients with non-valvular 
AF, 90% of thrombi are present in the LAA [3]. Thrombi 
detected in the LAA as well as a reduced LAA peak flow 
velocity were identified as independent predictors of an 
increased thromboembolic risk [4, 5] and also for recur-
rent stroke among these patients [6]. Therefore, the 
 rationale of LAA occlusion bases on 
its exclusion as an embolic source. 
The remaining other sources of em-
bolism do not warrant oral antico-
agulation (OAC) with its inherent 
risk for major bleeding. 
History of transcatheter left atrial appendage 
occlusion
The prototype LAA occlusion device called PLAATO 
(Percutaneous Left Atrial Appendage Transcatheter 
Occlusion) was meant to plug the LAA (fig. 1). It was 
conceived by the electrophysiologist Michael Lesh who 
assisted when Horst Sievert performed the first such 
intervention on 30 August 2001 [7]. The PLAATO de-
vice had numerous drawbacks and the implantation 
technique was difficult. Nevertheless clinical results 
were favourable [8], encouraging development and use 
of newer, simplified devices.
On 15 June 2002 percutaneous LAA closure with-
out general anaesthesia or echocardiographic guidance 
in awake patients was introduced by Bernhard Meier 
using the technically simpler Amplatzer technique [9], 
utilising the double-disc devices for atrial septal defect 
(ASD) or patent foramen ovale (PFO) closure. The disc 
designed for the right side of the interatrial septum in 
ASD or PFO closure covered the orifice of the LAA rem-
iniscent of the pacifier plate outside a toddler’s mouth 
(pacifier principle). The dedicated Amplatzer Cardiac 
Plug (ACP) (fig. 1) and LAA delivery sheath were intro-
duced in 2008. 
On 12 August 2002 the WATCHMAN device (fig. 1) 
was clinically introduced by Eugen Hauptmann and 
Eberhard Grube. It has since undergone several modi-
fications and is approved in many countries worldwide. 
To date, it is the only device for which data from a ran-
domised trial have been published [10].
In 2010, an LAA patch was introduced by Elefthe-
rios Sideris [11], while other devices are currently in 
early animal or human trials (e.g. WaveCrest from Co-
herex, Occlutech, Gore, and Lifetech) (fig. 1). The LAR-
IAT technique is a deviceless hybrid intervention com-
bining transcatheter with surgical elements [12, 13].
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Current devices and techniques
Technical description
Two alternative catheter-based concepts for LAA ex-
clusion are closure of the LAA cavity with a mechanical 
device from inside (endocardial approach)[8–10, 14, 15] 
or percutaneous suture ligation of the LAA at the level 
of its orifice from outside using an epicardial approach 
[13]. Currently, four devices are commercially available 
for endocardial occlusion, the WATCHMAN device, the 
ACP, the LAA Patch, and the WaveCrest device (fig. 1). 
The LARIAT device is used for percutaneous epicardial 
suture ligation. All these methods have CE-mark ap-
proval. 
The WATCHMAN device (fig. 1) consists of a ni-
tinol cage with an ultra-thin synthetic membrane cov-
ering its left atrial surface. The fixation barbs on the 
portion opposite the circumference of the LAA mini-
mise the risk of dislodgement. It is attached to a deliv-
ery cable and advanced via a 14 French (F) outer dia-
meter single or double curve sheath chosen according 
to operator judgement. Before or following transseptal 
puncture in a conventional manner (a low posterior 
puncture 
location is preferred to allow coaxial alignment with 
the appendage) intravenous heparin is administered 
maintaining an activated clotting time (ACT) >250 sec-
onds and a pigtail catheter is positioned into the LAA 
over a soft J-tip 0.035 inch wire. Angiography is per-
formed in several views (typically right anterior oblique 
caudal and cranial projections) delineating the append-
age shape and size. Device oversizing by 10–20% more 
than the diameter of the landing zone (measured from 
the area of the left circumflex coronary artery across 
the LAA to approximately 1 cm inward from the tip of 
the ridge separating LAA and left upper pulmonary 
vein) is mandatory. Subsequently, a stiff J-tip 0.035 
inch wire is advanced into the distal LAA and the pig-
tail catheter and transseptal sheath are exchanged for 
the access sheath while maintaining wire position. 
Some operators prefer to place the stiff 0.035 inch wire 
into the left upper pulmonary vein across the transsep-
tal sheath before exchanging it for the access catheter. 
Subsequently, a pigtail catheter is again advanced 
through the access sheath to the LAA to guide the ac-
cess sheath that has three markers corresponding to 
device size when it is advanced into the LAA until the 
distal marker aligns with the ostial plane of the ap-
pendage. After de-airing, the device is advanced via a 
delivery catheter to the distal access sheath, which to-
gether with the delivery catheter is slowly withdrawn 
while maintaining device position until it unfolds. 
Once deployed, appropriate position and fixation are 
confirmed via angiography, TOE, and a tug test (dem-
onstrating simultaneous movement of the device and 
appendage). Optimal position yields minimal protru-
sion beyond the orifice as well as complete ostial cover-
age with no or minimal (<5 mm by colour Doppler) re-
sidual flow and gentle compression of the device com-
paring the diameter of the implanted device with its 
original given diameter. Once adequate positioning 
confirmed, the device is released. Otherwise it can be 
retrieved and repositioned or exchanged.
The ACP (fig. 1) consists of a cylindrical nitinol 
Figure 1
Clinically used occluders for left atrial 
appendage closure and their manufacturers.
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cage (lobe) crowned by fixation hooks to secure the de-
vice in the LAA body. It is connected by a short flexible 
waist to a slightly larger nitinol plate (disc) destined to 
cover the LAA ostium. The flexible waist facilitates po-
sitioning and adaptation to heterogeneous anatomies. 
Unlike the WATCHMAN device, the length of the ACP 
is shorter than its diameter, which enables the ACP to 
be implanted in relatively short LAAs (implantation 
can in fact be attempted in virtually all LAAs). Femo-
ral venous access (sheath size 9 to 13 F inner diameter 
depending on the device size), transseptal puncture, 
LAA angiography, and TOE imaging (not used in some 
centres), as well as delivery sheath positioning are per-
formed in a similar manner as described for the 
WATCHMAN device (fig. 2). The delivery sheath is po-
sitioned in the body of the LAA while the lobe is pushed 
out. Angiographic control of the position may be done 
at this point. Then the disc is unfolded by pulling the 
sheath while fixing the device. With optimal position-
ing, the lobe should be visibly compressed (tyre-shaped) 
and adequately separated from the disc to which it is 
connected by a stretched waist. The disc should be 
slightly pulled into the LAA (concave appearance) 
while covering its entire ostium or most of it. After con-
firmation of an optimal position, the ACP is released, 
otherwise it may be retracted, repositioned, or ex-
changed.
An epicardial approach for LAA closure leaving no 
device behind but only suture material has been pro-
posed. A lasso-like suture, LARIAT snare, is positioned 
by a percutaneous pericardial puncture technique from 
the epicardial surface at the base of the LAA and tight-
Figure 2
Amplatzer Cardiac Plug (ACP) implantation procedure guided by fluoroscopy. 
Top left:  Angiographic depiction of left atrial appendage (LAA) in a right anterior oblique projection. The inserts show prior transoesophageal 
echocardiography (TOE) pictures with a patent foramen ovale (PFO) used for transseptal passage and the LAA in the projection 
corresponding to angiography.
Top right: Angiographic assessment of deployed Amplatzer Cardiac Plug (ACP) after tug test but before (pre) release. 
Bottom left: Angiographic documentation after (post) release.
Bottom right: Situation after closure of the PFO through the same TorqVue sheath.
F = French; LA = left atrium; LV = left ventricle; PV = pulmonary vein; y = years.
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ened followed by suture ligation. First, epicardial ac-
cess is obtained in a similar way as for some electro-
physiologic ablations [16], then a soft-tip 14 F access 
cannula is placed into the pericardial space. Second, a 
femoral venous access is established and transseptal 
puncture performed in a conventional manner. A spe-
cially designed magnet-tip 0.025 inch endocardial 
guide wire is advanced into the LAA apex followed by 
a balloon-mounted catheter via a 8.5 F delivery sheath 
and its position is confirmed via contrast injection 
through the balloon catheter lumen. Via the percutane-
ous epicardial access sheath a second 0.035 inch mag-
net-tip epicardial wire is advanced toward the LAA and 
aligned with a magnet located at the distal end of the 
endocardial wire already located in the LAA apex. Fi-
nally, the lasso delivered via the epicardial sheath over 
the epicardial wire ensnares the LAA ostium and is 
tightened. Successful occlusion is confirmed by TOE 
and angiography and the suture is knotted, followed by 
removal of the endocardial and epicardial gear. 
Clinical results
WATCHMAN
Although introduced in 2002, first clinical results were 
not published until 2007 [17]. The WATCHMAN device 
is the only LAA occlusion device so far that has been 
evaluated in a published prospective, controlled, ran-
domised trial. The PROTECT-AF trial examined its ef-
ficacy and safety in 707 patients with non-valvular 
atrial fibrillation (average CHADS
2
 score = 2.2 and 
CHA
2
DS
2
-VASc score = 3.4) in a non-inferiority design 
against chronic warfarin therapy [10]. Per protocol all 
patients were treated with warfarin for 45 days after 
device implantation to facilitate device endocardialisa-
tion. Warfarin was stopped if TOE examination (per-
formed after 45 days, 6 months, and 1 year) showed 
either complete closure of the LAA or if there was re-
sidual peri-device flow of <5 mm in width. Extended 
follow-up data from 1500 patient-years [18] show that 
87% of patients discontinued oral anticoagulation at 
45 days and 94% after 2 years of follow-up. Efficacy 
which was assessed by a primary composite endpoint of 
stroke, cardiovascular death, and systemic embolism 
was at 1065 patient-years of follow-up non-signifi-
cantly different between groups (3.0 per 100 patient-
years [95% credible interval 1.9–4.5] in the interven-
tion group and 4.9 per 100 patient-years [2.8–7.1] in 
the control group [rate ratio 0.62, 95% credible interval 
0.35–1.25]). Although there was a higher rate of ad-
verse safety events in the intervention group than in 
the control group, due mainly to periprocedural compli-
cations (pericardial effusion and procedural stroke 
 related to air embolism), the effect of increased opera-
tor experience was demonstrated in the more recent 
Continued Access Protocol (CAP) registry with shorter 
procedural time, greater procedural success, less proce-
dural complications, and higher warfarin discontinua-
tion rate [19]. 
Although peri-device flow is frequently observed 
after WATCHMAN implantation (some degree of peri-
device flow was reported in 47% at 45 days and 33% at 
12 months), when compared to patients with complete 
closure there was no difference in thromboembolic 
events in those with any peri-device flow regardless of 
whether or not anticoagulation was continued [20].
A recently performed analysis of the net clinical benefit 
(difference between the annualised rate of serious 
events in the WATCHMAN group and the rate in the 
warfarin group, assigning different weights to the 
events according to severity) in PROTECT-AF and 
CAP, demonstrated an increased net clinical benefit 
with higher CHADS
2
 scores, especially when the 
WATCHMAN was used for secondary prevention in 
 patients with previous events [21]. The WATCHMAN 
device implantation was also associated with an im-
provement of quality of life compared to warfarin ther-
apy [18]. 
AMPLATZER device family
The ease of use and long record of low thrombophlebi-
tis of the Amplatzer devices for other indications led to 
their investigation for percutaneous LAA closure [9] 
only shortly after the first PLAATO device had been 
implanted [7]. With the PLAATO device abandoned, 
the Amplatzer devices have the longest clinical follow-
up of currently available LAA occluders. The main 
drawback of non-dedicated Amplatzer devices was the 
lack of fixation hooks and unsuitable sheath configura-
tions which resulted in a high embolisation rate of 6% 
[9]. None of the available Amplatzer devices designed 
for closure of atrial or ventricular septal defects, patent 
ductus arteriosus, or vascular shunts proved adequate 
for LAA closure. This fact spurred the development of 
the dedicated ACP. The clinical outcome, however, in 
patients with technically successful Amplatzer LAA 
closure was already rewarding using the non-dedicated 
devices with 0.5 events per 100 patient-years compared 
to the expected 5.5 events without anticoagulation or 
1.8 events with anticoagulation according to the 
CHADS
2
 score. Notably, all patients were discharged 
on antiplatelet therapy only [22].
The ACP device with lobe sizes of 16 to 30 mm 
 diameter and a dedicated double curve sheath with a 
modified pusher cable has basically supplanted all 
other Amplatzer devices since its introduction. Initial 
registry data reflected the technical improvements 
with a reduction of the embolisation rate to approxi-
mately 2% across a wide range of observational studies 
[13, 14, 23–26]. Pericardial effusion leading to cardiac 
tamponade requiring interventions occurred in about 
2% as did neurological events. These figures are 
 comparable to those obtained with the PLAATO [8] or 
the WATCHMAN devices [10, 19]. In contrast to the 
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WATCHMAN device there are no strict anatomical or 
morphological contraindications (except visible mobile 
thrombus in the LAA, which is a general contraindica-
tion for non-surgical LAA occlusion) for an attempt at 
LAA closure with an ACP. Technical success in the first 
200 registry patients was 97% and a relevant thrombus 
on the device during follow-up TOE was seen in about 
3% [24]. The complete closure rate at sixth month TOE 
was 99%. This is considerably higher than what can be 
achieved with the WATCHMAN device. Long-term fol-
low-up data are lacking but design and material of the 
ACP are so close to that of non-dedicated Amplatzer 
 devices that clinical outcome can be expected to be 
 similar to that mentioned above [22].
Current data support the safety and efficacy of 
LAA occlusion with both WATCHMAN [27] and ACP 
 device implantation in patients with contraindications 
to even temporary anticoagulation but also in those 
amenable to warfarin. 
Indications for LAA occlusion
Patients with a contraindication 
to  anticoagulation 
Patients with a high thromboembolic risk (CHADS
2
 
score of >1) but contraindication to oral anticoagula-
tion (e.g., history of a significant bleeding event such as 
intracranial or major life-threatening bleeding of which 
the source has not been eliminated) represent the most 
accepted clinical indication for LAA occlusion, although 
such patients were not included the PROTECT-AF 
study.
Patients with an increased bleeding risk 
 under systemic anticoagulation 
Risk assessment using the HAS-BLED score as well as 
individual evaluation are mandatory. Non-vitamin K 
antagonist OACs (NOACs) shown to be associated with 
a lower bleeding risk than vitamin K antagonists may 
sufficiently reduce this risk. Those in whom vitamin K 
antagonists and even NOACs are considered to pose an 
unacceptable bleeding risk but who remain at high 
stroke risk (CHADS
2
 score of >1) should be treated 
with LAA closure. This also includes patients with an 
indication for triple anticoagulant therapy, e.g., multi-
ple coronary stents and AF fibrillation. This causes a 
significant increase in bleeding risk [28], avoidable by 
LAA occlusion. Patients should be able, however, to 
 receive double antiplatelet therapy for some weeks fol-
lowed in most cases by life-long single antiplatelet drug 
therapy. If not even short-term antiplatelet therapy is 
possible, percutaneous epicardial LAA closure may be 
an attractive option.
As alternative to oral anticoagulation when 
oral anticoagulation is possible: LAA occluder 
for every AF patient?
When patients are eligible for OAC and do not present 
an increased risk for bleeding, the option of LAA occlu-
sion should be discussed with the patient, although 
OAC currently remains the standard of care, as recom-
mended in an expert consensus document [29]. The ad-
vantages and disadvantages of both treatments should 
be explained in detail emphasising that randomised 
data currently are limited to a single study with a sin-
gle device comparing it in combination with warfarin, 
an oral vitamin K antagonist against warfarin [10]. It 
should be clarified that reported favourable results 
with LAA occlusion compared to oral vitamin K antag-
onists are based on observational studies and regis-
tries. In addition, it should be mentioned that, though 
the long-term outcome after LAA occlusion (taking into 
account periprocedural adverse events) may be equiva-
lent to anticoagulation with vitamin K antagonists, se-
rious complications related to the procedure itself (in-
cluding, but not limited to, the risk of death, stroke, and 
emergency surgery) may occur. Finally, patients should 
be alerted to the fact that NOACs are available which, 
compared to oral vitamin K antagonists, have at least 
equivalent efficacy, lower rates of intracranial and 
some agents, also of overall haemorrhage. They do not 
require surveillance of therapeutic levels. Finally, the 
decision should be made by a well-informed patient in 
collaboration with the treating physician.
Conclusion
Although the PROTECT-AF trial has established LAA 
closure as equally effective as warfarin, current clinical 
indications are restricted in most centres to patients 
having complications with, or contraindications to, 
OAK, or refuse it. This is mainly due to safety issues of 
current devices. Improvements in devices and tech-
niques for transcatheter LAA occlusion are expected. 
The results of ongoing randomised trials are awaited to 
allow wide spread clinical application of this promising 
technique as a valid alternative for stroke prevention 
among AF patients. However, this option needs to be 
discussed with every patient with AF, currently, for 
most of them, it is only for educational purposes. 
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